The 6-gene OncoMasTR test may help clinicians optimise treatment decisions by providing reliable prognosis based on individual risk factors
New research has demonstrated that the OncoMasTR test can identify the risk for disease recurrence in patients with a common type of breast cancer.
The OncoMasTR is a novel test for breast cancer which predicts the likelihood of breast cancer spreading to a separate part of the body, and of reappearing at a later date. This helps determine the risk profile for patients and facilitates doctors who are selecting their treatment options.
The research – involving detailed molecular analysis of samples from 404 women diagnosed with breast cancer from across 11 hospitals in Ireland were analysed – looked at how well the OncoMasTR test performs in comparison to several risk assessment tools in routine clinical use.
Risk factors used included the age of the patient, the size and grade of the tumour, as well as the commonly used molecular assay Oncotype Dx.
The research, which was published in the European Journal of Cancer, was led by University College Dublin (UCD), the Royal College of Surgeons in Ireland (RCSI) and OncoMark Limited. It found that OncoMasTR is the most accurate risk classifier for identifying patients with lower or higher risk for disease recurrence.
Each year, 2.2 million women are diagnosed with breast cancer around the world. Eighty percent (80%) of breast cancer patients have early-stage, hormone receptor positive disease.
Commenting on the findings, Professor William Gallagher, Deputy Director, Precision Oncology Ireland and Professor of Cancer Biology in UCD School of Biomolecular and Biomedical Science and Fellow, UCD Conway Institute who led the study said:
“This key clinical validation study showed that the OncoMasTR test has truly excellent performance in terms of predicting outcome of these patients, with improved performance versus the currently used approaches in the clinic. This may help clinicians to optimise treatment decisions.”
The research study was funded through grants from Science Foundation Ireland, the Irish Cancer Society and the European Union Horizon 2020 programme.